Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519945 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
A Phase 3 study of Ulcerative Colitis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,063
- Enrollment target
- 20
- Study locations
NCT03519945: Active Phase 3 study of Ulcerative Colitis, sponsored by Eli Lilly and Company.
NCT03519945 is a Phase 3 study of Ulcerative Colitis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,063 participants, below the 2,049-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03519945, a Phase 3 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,063 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Primary Outcome
Clinical remission based on the modified Mayo Score (MMS).
Conditions Studied
Interventions
- DRUG Mirikizumab
Study Locations (20)
Florida
- Direct Helpers Research Center - Hialeah
- Encore Borland-Groover Clinical Research - Jacksonville
- Wellness Clinical Research - Miami Lakes
- AdventHealth Orlando - Orlando
- Clintheory Healthcare - Orlando
- Gastroenterology Associates of Pensacola, PA - Pensacola
- Florida Medical Clinic LLC - Zephyrhills
California
- InSite Digestive Health Care - Arcadia
- Care Access - Berkeley - Berkeley
- Om Research LLC - Lancaster
- California Medical Research Associates - Northridge
- Inland Empire Clinical Trials, LLC - Rialto
- Clinical Applications Laboratories, Inc. - San Diego
Arizona
- Research Solutions of Arizona - Litchfield Park
- Valleywise Health Medical Center - Phoenix
Alabama
- Digestive Health Specialists - Dothan
Georgia
- Digestive Healthcare of Georgia - Atlanta
Idaho
- Grand Teton Research Group - Idaho Falls
Illinois
- NorthShore University HealthSystem - Evanston Hospital - Evanston
Indiana
- Indiana University Health University Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,063 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What the registry record for NCT03519945 still lists
NCT03519945 is an interventional study that assigns participants to a tested intervention. Its 1,063 participants enrollment target places it among the larger protocols in the corpus, below the 2,049-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Mirikizumab is the first listed.
NCT03519945 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03519945 about?
NCT03519945 is a clinical study titled "A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)". This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of th...
What is the current status of trial NCT03519945?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,063 participants. The study started on 2018-07-18. Estimated completion is 2027-12.
What conditions does trial NCT03519945 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT03519945?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT03519945?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03519945 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03519945's enrollment target sits among peer trials
1,063 9th of 122 higher than 114 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI